Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Caitlin E. Cox

April 10, 2024

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Conference News SCAI 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

L.A. McKeown

May 24, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Features

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

L.A. McKeown

December 02, 2022

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Conference News AHA 2020

AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF

L.A. McKeown

November 13, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content